99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Prospective Trial of 99Tc-MDP and Fosamax in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis Treated With Supraphysiological Doses of Thyroid Hormone
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
A NA clinical study on Differentiated Thyroid Cancer and Osteoporosis, this trial is completed. The trial is conducted by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and has accumulated 14 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Dec 2021 — Dec 2022 [monthly]
Completed NA
▶ Show 9 earlier versions
-
Nov 2021 — Dec 2021 [monthly]
Completed NA
-
Jan 2021 — Nov 2021 [monthly]
Completed NA
-
Aug 2020 — Jan 2021 [monthly]
Completed NA
Status: Recruiting → Completed
-
Aug 2019 — Aug 2020 [monthly]
Recruiting NA
-
Oct 2018 — Aug 2019 [monthly]
Recruiting NA
-
Aug 2018 — Oct 2018 [monthly]
Recruiting NA
-
Jul 2018 — Aug 2018 [monthly]
Recruiting NA
-
Jun 2018 — Jul 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .